Image courtesy: Twitter/ @adarpoonawalla 
National

SII manufacturing first batch of Covovax COVID-19 vaccine, says Poonawalla

The first batch of Covovax, a COVID-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India’s Pune facility, SII CEO Adar Poonawalla said on Friday.

migrator

Pune

"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia," Poonawalla said in a tweet. 

In March this year, he had said that the clinical trials of Covovax vaccine have begun in India and the company hopes to launch it by September this year. In August 2020, American vaccine company Novavax Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India. In January this year, the Serum Institute had rolled out Covishield vaccine in the country. It had entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Chennai: Gold touches 2025 high; sovereign tops Rs 1.02 lakh on December 23

Two weeks after wedding, techie couple found dead in Kundrathur

Chennai Citizen Connect: Encroached, damaged pavements push pedestrians to busy road

Madras HC judges inspect Marina Beach over shop allotment

Fatal accidents in Chennai down by 10 % in 2025, says police